K-3505

K-3505 is an orally administered, gut-restricted small molecule therapeutic developed by Kallyope, Inc. for the treatment of migraine. Utilizing Kallyope's proprietary platform focused on the gut-brain axis, K-3505 is designed to act locally within the gastrointestinal tract to modulate neural or hormonal signaling pathways—potentially involving 5-HT3 receptors—that communicate with the brain to influence migraine pathophysiology. By remaining gut-restricted, the compound aims to provide therapeutic benefit while avoiding the systemic exposure and associated side effects typical of other migraine medications. Clinical development progressed to Phase 1 trials in Australia; however, a planned Part II study to further assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers was withdrawn in 2023 due to a change in the sponsor's development strategy, and the asset is no longer a primary focus of the company's active clinical pipeline.